Sunday, 19 August 2018

Hebron Technology to expand in Healthcare Industry Solutions

13 June 2018 | News

In addition, as part of its growth plan, management of the Company plans to introduce advanced medical equipment and medical technology as well as invest in healthcare-related upstream and downstream companies.

Source: Blue Diamond Gallery

Source: Blue Diamond Gallery

Hebron Technology Co., Ltd., a developer, manufacturer and installer of valves and pipe fittings for use in the pharmaceutical, biological, food and beverage, and other clean industries has announced its strategic business development plan, designed to allow the company to expand from being a pharmaceutical production equipment and process pipeline provider into an integrated service provider in the healthcare field.

As previously disclosed, on March 10, 2018 Hebron acquired 49% of Xuzhou Weijia Biotechnology Co., Ltd., for R&D, sales of health foods, nutritional supplements, and other health-related products, and access to distribution channels and relationships with major pharmaceutical and health care related product manufacturers. In addition, as part of its growth plan, management of the Company plans to introduce advanced medical equipment and medical technology as well as invest in healthcare related upstream and downstream companies.

Mr. Anyuan Sun, Chairman and Chief Executive Officer of Hebron, commented, "While we continue to grow our core business of providing comprehensive process pipeline systems and engineer designs, installations and services for pharmaceutical factories, we also see a great opportunity to expand our market share in the pharmaceutical sector while developing new product and service offerings in other healthcare segments, such as medical equipment, as well as health food and beverage markets."

Mr. Sun continued, "We are excited about the potential of our development plan. We expect that our increased focus on new business initiatives will lead to more innovative and breakthrough product introductions over the coming years. This plan is a significant first step toward creating a portfolio of brands that are laser-focused on the healthcare field and leverages the strengths of our company."

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Is provision of cheap drugs having limited effects in the fight against HCV in SE Asia?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls